Form 4: MapLight CSO Sells Shares for Tax Obligations

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, disposed of 45,055 common shares at $17.98 to cover tax withholding obligations.

Summary

• James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., disposed of 45,055 shares of Voting Common Stock.
• The transaction occurred on January 27, 2026, at a price of $17.98 per share.
• This disposition was to satisfy tax withholding obligations related to the settlement of restricted stock unit awards.
• Following this transaction, Mr. Lillie beneficially owns 291,132 shares directly.
• The remaining shares held by Mr. Lillie are subject to a 180-day lock-up agreement from the initial public offering's final prospectus date of October 26, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine administrative transaction for tax purposes related to executive compensation, not indicative of a change in company fundamentals or insider sentiment.

Positives

• The transaction is a routine tax withholding, indicating the vesting of restricted stock units, which can be seen as a positive for the executive's compensation.

Negatives

• A reduction in direct share ownership by a key executive, even for tax purposes, slightly decreases their direct equity stake.

Future Outlook

The Chief Scientific Officer's remaining shares are subject to a lock-up agreement, restricting sales or transfers for 180 days following the initial public offering's final prospectus date of October 26, 2025, implying the lock-up will expire around April 24, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, such as tax-related dispositions of shares, are routine disclosures in the public markets. These transactions are common for executives receiving equity compensation and typically do not reflect a change in management's confidence in the company's prospects, unlike open market sales.

Comparison to Industry Standards

• This transaction, involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units, is a standard practice for executive compensation in publicly traded companies across various industries. It aligns with typical equity compensation plans and tax compliance procedures, similar to practices observed at companies like Pfizer or Moderna for their executives' RSU settlements.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related transaction by an insider, not an open-market sale reflecting a change in sentiment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The lock-up agreement for the reporting person's remaining shares is expected to expire around April 24, 2026.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Chief Scientific Officer, James Woodruff Lillie, Lock-up Agreement